Propensity Score Matched Study of Tri-Weekly vs. Weekly Platinum-Based Chemotherapy Concurrent with Radiotherapy in the Treatment of Locally Advanced Cervical Cancer

Autor: Kullathorn Thephamongkhol, Arb-aroon Lertkhachonsuk, Chomporn Sitathanee, Petch Alisanant, Napapat Amornwichet, Chonlakiet Khorprasert, Jidapa Bridhikitti, Pornpim Korpraphong, Kobkun Muangsomboon, Sith Phongkitkarun, Saowanee Srirattanapong, Duangkamon Prapruttam, Thaworn Dendumrongsup, Kewalee Sasiwimonphan, Chamnan Tanprasertkul, Mantana Dhanachai, Jayanton Patumanond, Jiraporn Setakornnukul

Publikováno v: Siriraj Medical Journal, Vol 74, Iss 4, Pp 245-255 (2022)

Objective: To compare tumor control and toxicity between tri-weekly chemotherapy and weekly platinum-based chemotherapy in locally advanced cervical cancer using the propensity score matching method. Material and Methods: DESIGN: Retrospective cohort

Externí odkaz: https://doaj.org/article/5ad8927badc640c2a608ff4bd146bea2

The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer

Autor: K. E. Borisov

Publikováno v: Опухоли женской репродуктивной системы, Vol 0, Iss 1, Pp 102-112 (2014)

The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant re

Externí odkaz: https://doaj.org/article/8259c53c6f7349f48488cdcb67078313

Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice‐Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single‐Blind Randomized Study

Autor: Yuji Kumagai, Kosuke Tanaka, Toshitsugu Sugimoto, Atsushi Ose

Publikováno v: Clinical Pharmacology in Drug Development

Once‐weekly injection of 56.5‐μg teriparatide formulation is a potent therapeutic agent for osteoporosis treatment. However, this treatment has an issue of difficulty in continuing the treatment by its adverse side effects including nausea, vomi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c23d7ba45b347d13fd0f9cac01be0e2
https://doi.org/10.1002/cpdd.687

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies

Autor: Leleu, X., Beksac, M., Chou, T., Dimopoulos, M., Yoon, S.S., Prince, H.M., Pour, L., Shelekhova, T., Chari, A., Khurana, M., Zhang, J., Obreja, M., Qi, M., Oriol, Albert, Siegel, D., Universitat Autònoma de Barcelona

Publikováno v: Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Recercat. Dipósit de la Recerca de Catalunya
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona

The regimen of carfilzomib, daratumumab, and dexamethasone (KdD) shows activity in patients with relapsed/refractory multiple myeloma. KdD at the twice-weekly 56 mg/m2 carfilzomib dose (KdD56) was used in the randomized phase 3 CANDOR study (NCT03158

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::779b523ac619c8875a4d6f63391fce45
http://hdl.handle.net/2072/445092

The role of topotecan in cancer ginecology treatment

Autor: V. V. Kosyy, A. G. Kedrova, D. A. Astakhov

Publikováno v: Opuholi Ženskoj Reproduktivnoj Sistemy, Vol 12, Iss 4, Pp 52-56 (2017)

The high morbidity, often latent, asymptomatic disease development is not optimal therapy in the first line, causes the development of the frequent recurrence of tumors, requiring second and thirds lines of chemotherapy. The use of topotecan in stand

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78d3f7d2974a2a8617fa95b2ac446e5f
https://doi.org/10.17650/1994-4098-2016-12-4-52-56